Fresenius Medical Care (FMEA) Q3 2026 Earnings Report

The call presented a mixed but generally constructive picture. Current operations showed stable group revenue, improving underlying profitability, strong Care Enablement growth, transformation savings, positive HV-HDF rollout progress, strong cash flow, and a solid leverage position. However, these positives were offset by a 6% decline in quarterly operating income excluding special items, a 1.1% decline in U.S. same-market treatments, higher-than-expected inflation, FDA audit findings, a lowered 2026 operating-income outlook, and an expected EUR 300 million-EUR 350 million 2027 TDAPA-related operating-income headwind. With meaningful operational progress but substantial reimbursement and execution challenges, the overall sentiment is balanced.

For 2026, management continues to expect broadly flat revenue development for the financial year on a constant currency basis and now expects operating income growth to be between flat and a negative mid-single-digit percentage growth rate compared to prior year; U.S. same market treatment growth is expected to decline approximately 0.9% for the full year, with Q4 expected to be slightly better than Q3 assuming a normal kind of flu season, while TDAPA is expected to be around a EUR 50 million headwind for the full year, including roughly about EUR 140 million in Q4, and inflation headwinds are now expected to exceed the EUR 300 million top end of the original range; the 5008X rollout is on track to convert 20% of our install base by the end of the year, FME25+ remains fully on track to deliver EUR 250 million in sustainable savings for the full year, China’s 2026 impact is expected to be around the EUR 50 million previously communicated, and ACA remains expected to be a EUR 50 million headwind in 2026; for 2027, management expects an operating income headwind between EUR 300 million and EUR 350 million based on the expiry that are TDAPA-related, an about a 1% contribution from the overall rate, and will provide a fuller outlook and assumptions with full year results in February.